Fig. 4: CK2 inhibition restores IKAROS’ ability to regulate MTOR expression in primary high-risk B-ALL with deletion of one IKZF1 allele. | Leukemia

Fig. 4: CK2 inhibition restores IKAROS’ ability to regulate MTOR expression in primary high-risk B-ALL with deletion of one IKZF1 allele.

From: Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia

Fig. 4

a MTOR mRNA level was measured by qRT-PCR in primary high-risk B-ALL samples following treatment with 10 μM CK2 inhibitor (CX-4945) for 2 days as compared to untreated (CTL) cells. b–d qChIP analysis of (b) IKAROS (c) H3K27me3, and (d) H3K9ac at the MTOR promoter. Untreated cells are (white and light gray bars) compared to and CX-4945-treated primary high-risk B-ALL (dark gray and black bars). Patients 1, 5, and 6 are Hispanic/Latino. Graphed data are the mean ± SD of combined values from three independent experiments. *p < 0.05, ***p < 0.001, ****p < 0.0001.

Back to article page